Jesús
San Miguel Izquierdo
Consultor Investigador
![Foto de Jesús](/img/nophoto.png)
![Foto de University of Turin](/img/noimage_org.png)
University of Turin
Turín, ItaliaPublicaciones en colaboración con investigadores/as de University of Turin (63)
2023
-
Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation
Leukemia, Vol. 37, Núm. 7, pp. 1521-1529
-
Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)
Leukemia, Vol. 37, Núm. 6, pp. 1175-1185
-
Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia
Seminars in Hematology
2022
-
Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up': [Ann Oncol 2021; 32(3): 309-322
Annals of oncology : official journal of the European Society for Medical Oncology
-
Corrigendum: “Corrigendum to ‘Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’”: (Annals of Oncology (2022) 33(1) (117), (S0923753421044999), (10.1016/j.annonc.2021.10.001))
Annals of Oncology
-
LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma
Leukemia, Vol. 36, Núm. 5, pp. 1371-1376
-
Perspectives on the Risk-Stratified Treatment of Multiple Myeloma
Blood cancer discovery, Vol. 3, Núm. 4, pp. 273-284
-
Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project
Journal of Clinical Oncology, Vol. 364
2021
-
Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up
HemaSphere, Vol. 5, Núm. 2
-
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
Annals of Oncology, Vol. 32, Núm. 3, pp. 309-322
2020
-
Clinical features associated with COVID-19 outcome in multiple myeloma: First results from the International Myeloma Society data set
Blood, Vol. 136, Núm. 26, pp. 3033-3040
-
Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)
Leukemia, Vol. 34, Núm. 8, pp. 2000-2011
2019
-
Insights on Multiple Myeloma Treatment Strategies
HemaSphere, Vol. 3, Núm. 1
-
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial
The Lancet, Vol. 393, Núm. 10168, pp. 253-264
2018
-
Maintenance Treatment and Survival in Patients with Myeloma: A Systematic Review and Network Meta-analysis
JAMA Oncology, Vol. 4, Núm. 10, pp. 1389-1397
-
Prevention and management of adverse events of novel agents in multiple myeloma: A consensus of the European Myeloma Network
Leukemia, Vol. 32, Núm. 7, pp. 1542-1560
2017
-
A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)
Leukemia, Vol. 31, Núm. 1, pp. 107-114
-
Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study
British Journal of Haematology, Vol. 177, Núm. 3, pp. 404-413
-
Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth
British Journal of Haematology, Vol. 178, Núm. 6, pp. 896-905
-
Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the European myeloma network
Leukemia, Vol. 2017